Core Viewpoint - Kodiak Sciences Inc. has announced an upsized underwritten public offering of 6,956,522 shares at a price of $23.00 per share, aiming to raise approximately $160 million in gross proceeds before expenses [1]. Company Overview - Kodiak Sciences is a precommercial biotechnology company focused on retinal therapeutics, utilizing its ABC® Platform to develop next-generation retinal medicines aimed at preventing and treating blindness [5]. - The company is currently advancing three late-stage clinical programs, including Tarcocimab and KSI-501 in Phase 3 studies for retinal vascular diseases, and KSI-101 in Phase 3 studies for Macular Edema Secondary to Inflammation [5]. Offering Details - The public offering is expected to close on or about December 18, 2025, subject to customary closing conditions [1]. - Kodiak Sciences has granted underwriters a 30-day option to purchase an additional 1,043,478 shares at the public offering price [1]. - The offering is conducted under a shelf registration statement previously filed with the SEC, which was declared effective on June 2, 2023 [3].

PALO ALTO, Calif., Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that it has commenced an underwritten public offering of 6,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak Sciences expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 of shares of its common st ...